Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
August 20, 2019
Inventiva secures new patent in the US strengthening the protection of its lead product candidate lanifibranor
Daix (France), August 20, 2019 – Inventiva (IVA.NX), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas ...
August 20, 2019
Basilea reports significantly increased cash-generating revenue, flat operating expenses and reduced net loss for half-year 2019
Basel, Switzerland, August 20, 2019 – Basilea Pharmaceutica Ltd. (BSLN.SW) announced today its financial results for the first six months of its financial year 2019, ...
August 20, 2019
Entera Bio Reports Second Quarter 2019 Financial Results and Provides Operating Update
JERUSALEM and BOSTON, Aug. 20, 2019 (GLOBE NEWSWIRE) --  Entera Bio Ltd. (ENTX) today provided a corporate update and reported financial results for second quarter ...
August 20, 2019
Kuros Biosciences Reports Results for First Half 2019
SCHLIEREN (ZURICH), Switzerland, Aug. 20, 2019 (GLOBE NEWSWIRE) -- Kuros Biosciences, a leader in next generation bone graft technologies, today reported its results for the ...
August 20, 2019
Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection
PALO ALTO, Calif., Aug. 20, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare ...
August 20, 2019
Outlook Therapeutics Completes Patient Enrollment for NORSE 1 a Phase 3 Clinical Trial for ONS-5010 in Wet AMD
CRANBURY, N.J., Aug. 20, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (OTLK) (the “Company”), a late clinical-stage biopharmaceutical company focused on developing ONS-5010, an ophthalmic ...
August 20, 2019
Genkyotex Extends Conversion Period for Outstanding €1.6 Million Convertible Debt by 12 Months
ARCHAMPS, France, Aug. 20, 2019 (GLOBE NEWSWIRE) -- Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX), a biopharmaceutical company and the leader in NOX therapies, ...
August 14, 2019
NeuBase Therapeutics Reports Financial Results for the Fiscal Third Quarter of 2019
PITTSBURGH, Aug. 14, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to address ...
August 14, 2019
Y-mAbs Announces Second Quarter 2019 Financial Results and Recent Corporate Developments
NEW YORK, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB) a late-stage clinical biopharmaceutical company focused on the development ...
August 14, 2019
Armata Pharmaceuticals Announces Second Quarter Results and Provides Corporate and Clinical Update
MARINA DEL REY, Calif., Aug. 14, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on ...
August 14, 2019
OncoCyte Provides Corporate Update and Reports Second Quarter 2019 Financial Results
ALAMEDA, Calif., Aug. 14, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, ...
August 14, 2019
InflaRx Reports Second Quarter 2019 Financial & Operating Results
JENA, Germany, Aug. 14, 2019 (GLOBE NEWSWIRE) --  InflaRx (IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today reported financial ...
August 14, 2019
Outlook Therapeutics Provides Business Update and Reports Financial Results for Third Quarter of Fiscal 2019
CRANBURY, N.J., Aug. 14, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (OTLK) (the “Company”) today reported business highlights and financial results for its third quarter ...
August 2, 2019
Santhera Announces Closing of Licensing Transaction with Chiesi Group for Raxone® in LHON
Pratteln, Switzerland, August 2, 2019 – Santhera Pharmaceuticals (SANN.SW) announces the closing of the licensing transaction with Chiesi Farmaceutici, an international research-focused healthcare group (Chiesi Group). ...
August 2, 2019
Bionano Genomics to Report Second Quarter 2019 Financial Results and Host a Conference Call and Webcast on August 8
SAN DIEGO, Aug. 02, 2019 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ...
August 2, 2019
Athenex Provides an Update Regarding the Vasopressin Case
BUFFALO, N.Y., Aug. 02, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies ...
August 2, 2019
Neovasc to Announce Second Quarter 2019 Financial Results on Wednesday, August 7th
VANCOUVER, Aug. 2, 2019 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve ...
August 2, 2019
Arcturus Therapeutics Announces $2.3 Million Additional Registered Direct Offering of Common Stock
SAN DIEGO, Aug. 02, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (“Arcturus” or the “Company”), a leading RNA medicines company focused on the discovery, development and ...
August 1, 2019
DURECT Corporation Announces Second Quarter 2019 Financial Results and Update of Programs
DURECT Corporation (DRRX) today announced financial results for the three months ended June 30, 2019 and provided a corporate update. Total revenues were $4.0 million ...
August 1, 2019
Chiasma to Report Second Quarter Financial Results on August 8, 2019
WALTHAM, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and ...
Page 1 of 158